T1	Participants 112 159	patients with untreated acute myeloid leukemia.
T2	Participants 414 555	In 1996, survival data were updated from three prospective, randomized comparisons of idarubicin and daunorubicin that began in 1984 and 1985
T4	Participants 23 46	three randomized trials
T3	Participants 557 710	These were trials of the Memorial Sloan-Kettering Cancer Center (MSKCC), the U.S. Multicenter Study Group, and the Southeastern Cancer Study Group (SEG).
